DGAP-Adhoc: STRATEC's Birkenfeld site suffers water damage

STRATEC Biomedical AG / Key word(s): Miscellaneous

05.06.2013 15:47

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

STRATEC's Birkenfeld site suffers water damage

Birkenfeld, June 5, 2013

STRATEC Biomedical AG (Frankfurt: SBS; Prime Standard, TecDAX) reported
today that the heavy rains that fell in the past few days have caused
surface water to damage several buildings at STRATEC's complex in
Birkenfeld, Germany.

Although the clean-up process has now been largely completed, business
operations at the Birkenfeld site are likely to be affected for a period of
several weeks. Particularly, some delays in services such as project
deliverables are to be expected.

The aforementioned service delays will primarily affect the 'Prototyping'
and 'Reliability Testing' divisions, leading to postponed recognition of
revenue that could be as high as EUR 3 million. The impact on revenue and
earnings will mainly be felt the in the second quarter of 2013. Due to the
current uncertainties, the publication of the financial guidance for 2013
and subsequent years, which was slated for June 2013, will now coincide
with the publication of the half-yearly results for 2013 scheduled to take
place on July 23, 2013.

An insurance claim will be made for the full extent of material and
business interruption damages.

---------------------------------------------------------------------------

Information and Explaination of the Issuer to this News:

About STRATEC

STRATEC Biomedical AG (www.stratec.com) designs and manufactures fully
automated analyzer systems for its partners in the fields of clinical
diagnostics and biotechnology. These partners market such systems, in
general together with their own reagents, to laboratories, blood banks and
research institutes around the world. The company develops its products on
the basis of its own patented technologies.

Shares in the company (ISIN: DE0007289001) are traded in the Prime Standard
segment of the Frankfurt Stock Exchange and are listed in the TecDAX select
index of the German Stock Exchange.

Further information can be obtained from:

STRATEC Biomedical AG
André Loy, Investor Relations
Gewerbestr. 37, 75217 Birkenfeld
Germany
Tel: +49 7082 7916-190
Fax: +49 7082 7916-999
ir@stratec.com
www.stratec.com

---------------------------------------------------------------------------

Language: English
Company: STRATEC Biomedical AG
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: info@stratec.com
Internet: www.stratec.com
ISIN: DE0007289001
WKN: 728900
Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------